Metraipolis › archive › dc_3ea129488267

Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial — Europe PMC PMID:41012186

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41012186
DOI: 10.3390/vaccines13090984
License (as archived): solo-consultazione
Archived: 2026-11-09T20:55:05.610Z
SHA-256 of the archived text: e69d9f93a4f7412d54399e6e069a605e14d22d2aa70860c09dd106ac1a2230c8
Stable URL of this page: https://metraipolis.com/documento/dc_3ea129488267

How to cite

Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial — Europe PMC PMID:41012186 — Europe PMC (en), https://europepmc.org/article/MED/41012186 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3ea129488267 (Metraipolis archive dc_3ea129488267, sha256 e69d9f93a4f7412d54399e6e069a605e14d22d2aa70860c09dd106ac1a2230c8)

BibTeX

@misc{dc3ea129488267,
  title = {Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial — Europe PMC PMID:41012186},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41012186},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3ea129488267; sha256 e69d9f93a4f7412d54399e6e069a605e14d22d2aa70860c09dd106ac1a2230c8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41012186. Agents can read the archived copy with the MCP tool read_document.